Head-to-head · Cost-Efficiency Index
SkinnyRx vs Trillium Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
SkinnyRx
Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Visit SkinnyRxTrillium Meds
Cost-first shoppers who want all-50-state compounded GLP-1 with a real month-to-month option and a cheaper 3-month prepay path.
Visit Trillium MedsThe verdict
Trillium Meds takes it, leading the Cost-Efficiency Index 73 to 71. Trillium Meds is a small, Portland-OR-based telehealth platform connecting patients to independent licensed providers and compounding pharmacies for GLP-1 therapy, serving all 50 states plus Puerto Rico. SkinnyRx still earns a C — Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Trillium Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | SkinnyRx | Trillium Meds |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 73/100 |
| Semaglutide / mo | $349/mo month-to-month ($299 on 4 months, $249 on 6, $199 only on 12) | $159/mo (all doses, compounded) |
| Tirzepatide / mo | $399/mo month-to-month ($349 on 4 months, $329 on 6, $299 only on 12) | $249/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $4,188 | $1,908 |
| Tirzepatide / yr (modeled) | $4,788 | $2,988 |
| Coverage | Most states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #66 | #71 |
SkinnyRx
71/100Where the value is
- A complete four-term ladder for both molecules is published rather than gated, so the cost of not committing is knowable before signup
- Both compounded molecules are offered, with the same term structure on each
- The twelve-month rate is genuinely low for the category if a year is a commitment you were going to make anyway
The tradeoffs
- The '$199/month' it advertises everywhere is the TWELVE-MONTH rung. The rate you can stop after a month is $349 — 75% higher — and the figure appears without that term attached
- An FDA warning letter is on public record against Lean Rx, Inc. dba SkinnyRx, issued 20 February 2026. We disclose it and we do not treat it as disqualifying
Regulatory note: the FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx in February 2026. We still list and link to SkinnyRx; you should know the letter is on the public record before you decide.
Trillium Meds
73/100Where the value is
- Discloses both a real month-to-month rate ($159/$249) and the 3-month prepay rate, rather than only advertising the lower prepay number
- LegitScript certified, all 50 states plus Puerto Rico, with a real street address published
- Syringes and alcohol wipes included; Klarna and Affirm financing available
The tradeoffs
- The lowest advertised rate ($119/mo semaglutide, ~$200/mo tirzepatide) requires a $357 or $599 upfront 3-month payment, not a standing monthly charge
- Partner pharmacy names are referenced in the FAQ structure but were not visible in the page text pulled this session — re-verify before citing a specific pharmacy
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.